Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Geron Corp (GERN)

Geron Corp (GERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,109,709
  • Shares Outstanding, K 604,501
  • Annual Sales, $ 240 K
  • Annual Income, $ -184,130 K
  • EBIT $ -208 M
  • EBITDA $ -217 M
  • 60-Month Beta 0.51
  • Price/Sales 9,335.33
  • Price/Cash Flow N/A
  • Price/Book 7.55

Options Overview Details

View History
  • Implied Volatility 75.95% ( -31.39%)
  • Historical Volatility 37.02%
  • IV Percentile 62%
  • IV Rank 12.70%
  • IV High 521.72% on 05/29/24
  • IV Low 11.12% on 07/01/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 3,301
  • Volume Avg (30-Day) 1,168
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 90,251
  • Open Int (30-Day) 88,256

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.02
  • Number of Estimates 6
  • High Estimate 0.12
  • Low Estimate -0.12
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +77.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.45 +1.01%
on 12/20/24
4.20 -17.00%
on 11/27/24
-0.50 (-12.53%)
since 11/20/24
3-Month
3.45 +1.01%
on 12/20/24
4.75 -26.53%
on 09/23/24
-1.22 (-25.90%)
since 09/20/24
52-Week
1.64 +112.80%
on 03/13/24
5.34 -34.64%
on 06/12/24
+1.33 (+61.57%)
since 12/20/23

Most Recent Stories

More News
Geron (GERN) Q3 2024 Earnings Call Transcript

GERN earnings call for the period ending September 30, 2024.

GERN : 3.49 (-4.64%)
Geron: Q3 Earnings Snapshot

Geron: Q3 Earnings Snapshot

GERN : 3.49 (-4.64%)
Is This Penny Stock With 55% Upside A Buy Now?

This biotech company currently has an approved product on the market. However, there is more to the story than meets the eye.

$SPX : 5,930.85 (+1.09%)
GERN : 3.49 (-4.64%)
Geron (GERN) Q2 2024 Earnings Call Transcript

GERN earnings call for the period ending June 30, 2024.

GERN : 3.49 (-4.64%)
Geron: Q2 Earnings Snapshot

Geron: Q2 Earnings Snapshot

GERN : 3.49 (-4.64%)
Is Geron Stock a Buy Following Its First New Drug Approval?

Find out if the high-flying biotech stock can keep on climbing higher.

AMGN : 263.38 (+0.84%)
GERN : 3.49 (-4.64%)
Geron (GERN) Q1 2024 Earnings Call Transcript

GERN earnings call for the period ending March 31, 2024.

GERN : 3.49 (-4.64%)
Geron: Q1 Earnings Snapshot

Geron: Q1 Earnings Snapshot

GERN : 3.49 (-4.64%)
Stock Index Futures Tick Higher Ahead of U.S. Economic Data, Fed Meeting Awaited

March S&P 500 E-Mini futures (ESH24) are up +0.20%, and March Nasdaq 100 E-Mini futures (NQH24) are up +0.14% this morning as investors looked ahead to a new round of U.S. economic data and geared up for...

ESH24 : 5,101.67s (-1.01%)
NQH24 : 17,854.75s (-0.94%)
LEN : 138.08 (-0.23%)
ON : 65.50 (+1.08%)
NVDA : 134.70 (+3.08%)
FSR : 0.0897 (-28.13%)
DKS : 218.76 (+0.54%)
VNA.D.DX : 29.450 (+2.40%)
VOD.LN : 66.500 (-0.84%)
GERN : 3.49 (-4.64%)
ADBE : 447.17 (+2.24%)
ULTA : 430.01 (+1.06%)
Geron (GERN) Q4 2023 Earnings Call Transcript

GERN earnings call for the period ending December 31, 2023.

GERN : 3.49 (-4.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic...

See More

Key Turning Points

3rd Resistance Point 3.86
2nd Resistance Point 3.77
1st Resistance Point 3.63
Last Price 3.49
1st Support Level 3.40
2nd Support Level 3.31
3rd Support Level 3.17

See More

52-Week High 5.34
Fibonacci 61.8% 3.93
Fibonacci 50% 3.49
Last Price 3.49
Fibonacci 38.2% 3.05
52-Week Low 1.64

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar